108 related articles for article (PubMed ID: 26976325)
41. Differential effects of dopamine receptor subtype-specific agonists with respect to operant behavior maintained on a differential reinforcement of low-rate responding (DRL) schedule.
Chiang FK; Cheng RK; Liao RM
Pharmacol Biochem Behav; 2015 Mar; 130():67-76. PubMed ID: 25584855
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the effects of α2 adrenoceptor antagonism with the D2 receptor antagonist raclopride on conditioned avoidance responding in rats.
Jacobson SM; Prus AJ
Behav Pharmacol; 2010 Oct; 21(7):654-9. PubMed ID: 20729715
[TBL] [Abstract][Full Text] [Related]
43. The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia.
Malik P; Andersen MB; Peacock L
Pharmacol Biochem Behav; 2004 Aug; 78(4):805-10. PubMed ID: 15301939
[TBL] [Abstract][Full Text] [Related]
44. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease.
Linazasoro G;
J Neurol; 2004 Mar; 251(3):335-9. PubMed ID: 15015015
[TBL] [Abstract][Full Text] [Related]
45. Comparative effects of alpha-2 receptor agents and THA on the performance of adult and aged rats in the delayed non-matching to position task.
Sirviö J; Harju M; Riekkinen P; Haapalinna A; Riekkinen PJ
Psychopharmacology (Berl); 1992; 109(1-2):127-33. PubMed ID: 1365646
[TBL] [Abstract][Full Text] [Related]
46. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.
Le WD; Jankovic J; Xie W; Appel SH
J Neural Transm (Vienna); 2000; 107(10):1165-73. PubMed ID: 11129106
[TBL] [Abstract][Full Text] [Related]
47. Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Berghauzen-Maciejewska K; Kuter K; Kolasiewicz W; Głowacka U; Dziubina A; Ossowska K; Wardas J
Behav Brain Res; 2014 Sep; 271():343-53. PubMed ID: 24956561
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological insight into neurotransmission origins of resting-state functional connectivity: α2-adrenergic agonist vs antagonist.
Nasrallah FA; Low SA; Lew SK; Chen K; Chuang KH
Neuroimage; 2014 Dec; 103():364-373. PubMed ID: 25241086
[TBL] [Abstract][Full Text] [Related]
49. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
50. Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.
Cheah BC; Kiernan MC
IDrugs; 2010 Dec; 13(12):911-20. PubMed ID: 21154151
[TBL] [Abstract][Full Text] [Related]
51. The effect of repeated treatment with pramipexole on the central dopamine D3 system.
Maj J; Rogói Z; Margas W; Kata M; Dziedzicka-Wasylewska M
J Neural Transm (Vienna); 2000; 107(12):1369-79. PubMed ID: 11458990
[TBL] [Abstract][Full Text] [Related]
52. Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research.
Der-Avakian A; D'Souza MS; Pizzagalli DA; Markou A
Transl Psychiatry; 2013 Aug; 3(8):e297. PubMed ID: 23982629
[TBL] [Abstract][Full Text] [Related]
53. Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.
Izumi Y; Sawada H; Yamamoto N; Kume T; Katsuki H; Shimohama S; Akaike A
Eur J Pharmacol; 2007 Feb; 557(2-3):132-40. PubMed ID: 17161393
[TBL] [Abstract][Full Text] [Related]
54. Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.
Kim MK; Park HS; Cho JH; Kim GS; Won C
Neuroreport; 2015 Jan; 26(2):74-80. PubMed ID: 25514384
[TBL] [Abstract][Full Text] [Related]
55. Combined treatment with naloxone and the alpha2 adrenoceptor antagonist atipamezole reversed brain hypoxia induced by a fentanyl-xylazine mixture in a rat model.
Choi S; Irwin MR; Noya MR; Shaham Y; Kiyatkin EA
Neuropsychopharmacology; 2024 Jun; 49(7):1104-1112. PubMed ID: 38123817
[TBL] [Abstract][Full Text] [Related]
56. Single dose of a dopamine agonist impairs reinforcement learning in humans: behavioral evidence from a laboratory-based measure of reward responsiveness.
Pizzagalli DA; Evins AE; Schetter EC; Frank MJ; Pajtas PE; Santesso DL; Culhane M
Psychopharmacology (Berl); 2008 Feb; 196(2):221-32. PubMed ID: 17909750
[TBL] [Abstract][Full Text] [Related]
57. Rapid emergence from dexmedetomidine sedation in Sprague Dawley rats by repurposing an α
Xie Z; Fox AP
BMC Anesthesiol; 2023 Feb; 23(1):39. PubMed ID: 36721095
[TBL] [Abstract][Full Text] [Related]
58. Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment.
Ersche KD; Roiser JP; Lucas M; Domenici E; Robbins TW; Bullmore ET
Psychopharmacology (Berl); 2011 Apr; 214(4):779-89. PubMed ID: 21088959
[TBL] [Abstract][Full Text] [Related]
59. Pramipexole-induced disruption of behavioral processes fundamental to intertemporal choice.
Johnson PS; Stein JS; Smits RR; Madden GJ
J Exp Anal Behav; 2013 May; 99(3):290-317. PubMed ID: 23436721
[TBL] [Abstract][Full Text] [Related]
60. Effects of pramipexole on impulsive choice in male wistar rats.
Madden GJ; Johnson PS; Brewer AT; Pinkston JW; Fowler SC
Exp Clin Psychopharmacol; 2010 Jun; 18(3):267-76. PubMed ID: 20545391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
